1. Rieger L, Weller M, Bornemann A, Schabet M, Dichgans J, Meyermann R.
BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. J Neurol Sci 1998;155:68-75. (Impact factor 2,167)
2. Naumann U, Weit S, Rieger L, Meyermann R, Weller M. p27 modulates cell
cycle progression and chemosensitivity in human malignant glioma. Biochem Biophys Res Commun 1999;261:890-896. (Impact factor 2,595)
3. Roth W, Grimmel C, Rieger L, Strik H, Takayama S, Krajewski S, Meyermann
4. Dichgans J, Reed JC, Weller M. Bag-1 and Bcl-2 gene transfer in malignant
glioma: modulation of cell cycle regulation and apoptosis. Brain Pathol 2000;10:223-234. (Impact factor 4,741)
5. Rieger L, Rieger J, Winter S, Streffer J, Esser P, Dichgans J, Meyermann R,
Weller M. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo. Acta Neuropathol 2000; 99:555-562.
6. Rieger L, Kämmerer U, Hofmann J, Sütterlin M, Dietl J. Choriocarcinoma Cells
Modulate the Cytokine Production of Decidual Large Granular Lymphocytes in Coculture. Am J Reprod Immunol 2001; 46:137-144. (Impact factor 2,451)
Rieger L, Kämmerer U, Sütterlin M, Dietl J. HLA-G positive/negative Chorioncarcinomzellen modulieren die Zytokinproduktion der CD56++ dezidualen Lymphozyten. J Reprod Fertil 2001;3:27-31.
8. Steck T, Rieger L, Rodel E, Dietl J, Kämmerer U. Die Expression der Moleküle
HLA-G und HLA-E moduliert die Zytokinproduktion monozytengenerierter dendritischer Zellen. Zentralbl Gynakol 2002;124:304-309.
9. Rieger L, Hofmeister V, Probe C, Dietl J, Weiss EH, Steck T, Kämmerer U.
Th1- and Th-2-like cytokine production by first trimester decidual large granular lymphocytes is influenced by HLA-G and HLA-E. Mol Hum Reprod 2002;8:255-261. (Impact factor 3,506)
10. Kämmerer U, Rieger L, Kapp M, Dietl J, Ruck P. Immunocompetent cells in
the endometrium of fetuses and children. Hum Reprod. 2003 ;18:969-975. (Impact factor 4,357)
11. Sütterlin MW, Bussen SS, Rieger L, Dietl J, Steck T. Serum folate and Vitamin
B12 levels in women using modern oral contraceptives (OC) containing 20 microg ethinyl estradiol. Eur J Obstet Gynecol Reprod Biol. 2003;107:57-61. (Impact factor 1,764)
12. Rieger L, Bernar T, Girschick G, Rudiger T, Steck T, Dietl J. Placenta praevia
percreta – eine schwere Komplikation nach vorausgegangener Sectio caesarea. Zentralbl Gynakol. 2003;125:189-191.
13. Bussen S, Rieger L, Sütterlin M, Dietl J. Einfluss des Vascular endothelial
Growth Factor (VEGF) auf die Entwicklung der schweren Präeklampsie und des HELLP-Syndroms. Z. Geburtshilfe Neonatol. 2003;207:101-106.
14. Rieger L, Wessig C, Bussen S, Bartsch A, Sütterlin M, Dietl J. Reversibler
Visusverlust bei schwerer Präeklampsie – Fallbericht und Literaturübersicht. Z. Geburtshilfe Neonatol. 2003;207:228-231.
15. Thanner F, Sütterlin MW, Kapp M, Rieger L, Kristen P, Dietl J, Gassel AM,
Muller T. Heat-shock protein 70 as a prognostic marker in node-negative breast cancer. Anticancer Res. 2003;23:1057-1062. (Impact factor 1,656)
16. Honig A, Rieger L, Dietl J, Kämmerer U. Mechanisms regulating the
expression of indoleamine 2,3-dioxygenase during decidualization of human endometrium. Hum Reprod. 2004;19:2683-2684. (Impact factor 4,357)
17. Rieger L, Dietl J. A randomized comparison of total or supracervical
hysterectomy: surgical complications and clinical outcomes. Obstet Gynecol. 2004;103:581-582. (Impact factor 4,392)
18. Sütterlin MW, Bussen SS, Rieger L, Dietl J, Steck T. Reply to 'Letter to the
Editor' by Bor MV "Do we have any good reason to suggest restricting the use of oral contraceptives in women with pre-existing Vitamin B(12) deficiency?" Contraceptive use in women with pre-existing Vitamin B(12) deficiency. Eur J Obstet Gynecol Reprod Biol. 2004;115:241-242. (Impact factor 1,764)
19. Honig A, Rieger L, Kapp M, Sütterlin M, Dietl J, Kämmerer U. Indoleamine 2,3-
dioxygenase (IDO) expression in invasive extravillous trophoblast supports role of the enzyme for materno-fetal tolerance. J Reprod Immunol. 2004;61:79-86. (Impact factor 2,204)
20. Rieger L, Honig A, Sütterlin M, Kapp M, Dietl J, Ruck P, Kämmerer U. Antigen
presenting cells in human endometrium during the menstrual cycle compared to early pregnancy. J Soc Gynecol Invest 2004;11:488-493. (Impact factor 2,297)
21. Honig A, Rieger L, Kristen P, Eck M, Frambach T, Tschammler A, Caffier H,
Dietl J. A case of metastasizing invasive hydatidiform mole. Is less -less good? Review of the literature with regard to adequate treatment. Eur. J. Gynaecol. Oncol. 2005;26:158-162. (Impact factor 0,633)
22. Honig A, Rieger L, Sütterlin A, Dietl J, Sütterlin MW, Kämmerer U. Brain
metastases in breast cancer – an in vitro study to evaluate new systemic chemotherapeutic options. Anticancer Res. 2005;25:1531-1538. (Impact factor 1,656)
23. Thanner F, Sütterlin MW, Kapp M, Rieger L, Morr AK, Kristen P, Dietl J,
Gassel AM, Müller T. Heat Shock Protein 27 is associated with decreased survival in node-negative breast cancer patients. Anticancer Res. 2005;25:1649-1654. (Impact factor 1,656)
24. Honig A, Rieger L, Thanner F, Eck M, Sütterlin M, Dietl J. Placenta percreta
with subsequent uterine rupture at 15 weeks of gestation after 2 previous cesarean sections. J. Obstet. Gynaecol. Research 2005;31:439-443. (Impact factor 0,869)
25. Honig A, Rieger L, Kapp M, Dietl J, Kämmerer U. Immunohistochemistry in
human placental tissue – pitfalls of antigen detection. J Histochem Cytochem 2005;53:1413-1420. (Impact factor 2,381)
26. Honig A, Rieger L, Kapp M, Krockenberger M, Eck M, Dietl J, Kammerer U.
Increased tartrate-resistant acid phosphatase (TRAP) expression in malignant breast, ovarian and melanoma tissue: an investigational study. BMC Cancer. 2006 Jul 25;6:199. (Impact factor 3,153)
27. Krockenberger M, Honig A, Rieger L, Coy JF, Sutterlin M, Kapp M, Horn E,
Dietl J, Kammerer U.Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer. 2007;17:101-6. (Impact factor 1,558)
28. Engert S, Rieger L, Kapp M, Becker JC, Dietl J Kämmerer U. Profiling
chemokines, cytokines and growth factors in human early pregnancy decidua by protein array. Am J Reprod Immunol 2007;58:129-37 (Impact factor 2,451)
29. Djakovic A, Rieger L, Wirbelauer J, Kalla J, Dietl J. Schwere intrauterine
Wachstumsretardierung bei Uterus bicornis, Insertio velamentosa und vorzeitiger partieller Plazentalösung in der 26. Schwangerschaftswoche - eine Kasuistik. Z Geburtshilfe Neonatol 2007;211:169-73.
30. Engel JB, Honig A, Schönhals T, Weidler C, Häusler S, Krockenberger M,
Grunewald TG, Dombrowski Y, Rieger L, Dietl J, Wischhusen J. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation. Eur J Obstet Gynecol Reprod Biol. 2008;141:64-9. (Impact factor 1,764)
31. Segerer SE, Müller N, Brandt J, Kapp M, Dietl J, Reichardt HM, Rieger L,
Kämmerer U. The glycoprotein-hormones activin A and inhibin A interfere with dendritic cell maturation. Reprod Biol Endocrinol. 2008 6;6:17. (Impact factor 1,695)
32. Segerer S, Kammerer U, Kapp M, Dietl J, Rieger L. Upregulation of
chemokine and cytokine production during pregnancy. Gynecol Obstet Invest. 2009;67(3):145-50. (Impact factor 1,031)
33. Engel JB, Schönhals T, Weidler C, Häusler S, Krockenberger M, Rieger L,
Dietl J, Wischhusen J, Honig A. Tubulin inhibitor AEZS 112 inhibits the growth
of experimental human ovarian and endometrial cancers irrespective of caspase inhibition. Oncol Rep. 2009;22:361-7. (Impact factor 1,686)
34. Segerer SE, Müller N, van den Brandt J, Kapp M, Dietl J, Reichardt HM,
Rieger L, Kämmerer U. Impact of female sex hormones on the maturation and function of human dendritic cells. Am J Reprod Immunol. 2009;62:165-73. (Impact factor 2,451)
35. Rieger L, Segerer S, Bernar T, Kapp M, Majic M, Morr AK, Dietl J, Kämmerer
U. Specific subsets of immune cells in human decidua differ between normal pregnancy and preeclampsia--a prospective observational study. Reprod Biol Endocrinol. 2009 23;7:132. (Impact factor 1,695)
36. Wirbelauer J, Thomas W, Rieger L, Speer CP. Intrauterine growth retardation
in infants ≤32 weeks of gestation is associated with low white blood cell counts. Am J Perinatol. 2010 10:819-24. (Impact factor 1,118)
37. Ivanisevic M, Segerer S, Rieger L, Kapp M, Dietl J, Kämmerer U, Frambach T.
Antigen-presenting cells in pregnant and non-pregnant human myometrium. Am J Reprod Immunol. 2010;64:188-96. (Impact factor 2,451)
38. Frambach T, Wirbelauer J, Schelling P, Rieger L, Muellenbach RM, Roewer N,
Kranke P. [Patient-controlled intravenous analgesia with remifentanil as an alternative to epidural analgesia during labor: case series and discussion of medicolegal aspects]. Z Geburtshilfe Neonatol. 2010;214:145-50.
39. Boussaad I, Varagnolo L, Hornich V, Rieger L, Krockenberger M, Stuehmer T,
Kranzfelder D, Mueller AM, Schneider-Schaulies S. Wild-type measles virus interferes with short-term engraftment of human CD34+ hematopoietic progenitor cells. J Virol. 2011;85:7710-8. (Impact factor 5,189)
40. Segerer SE, Rieger L, Kapp M, Dombrowski Y, Müller N, Dietl J, Kämmerer U.
MIC-1 (a multifunctional modulator of dendritic cell phenotype and function) is produced by decidual stromal cells and trophoblasts. Hum Reprod. 2011 Nov 6. [Epub ahead of print] (Impact factor 4,357)
1. Rieger J, Roth W, Glaser T, Winter S, Rieger L, Dichgans J, Weller M.
Glioblastoma multiforme: mechanisms of resistance to chemotherapy. Neurol Psychiat BR 1999;7:37-46 (Impact factor 0,1)
2. Honig A, Rieger L, Sütterlin M, Dietl J, Solomayer EF. Preoperative
Chemotherapy and Endocrine Therapy in Patients with Breast Cancer. Clin Breast Cancer 2004;5:198-207. (Impact factor 2,790)
3. Honig A, Rieger L, Sütterlin M, Wallwiener D, Dietl J, Solomayer EF. State of
the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments. GMS Ger Med Sci 2005;3:Doc08 (20050913)
4. Dietl J, Hönig A, Kämmerer U, Rieger L. Natural Killer Cells and Dendritic
Cells at the Human Feto-Maternal Interface: An Effective Cooperation? Placenta 2006;27:341-347. (Impact factor 2,985)
5. Rieger, L; Hönig, A; Griesinger, G; Dietl, J; Engel, JB. In-Vitro-Fertilisation: Ein
ethisches Dilemma. Dtsch Arztebl 2007; 104(17): A 1146–50
6. Engel JB, Schally AV, Dietl J, Rieger L, Honig A. Targeted Therapy of Breast
and Gynecological Cancers with Cytotoxic Analogues of Peptide Hormones. Mol Pharm 2007 2007 ;4:652-8. (Impact factor 4,725)
7. The GnRH antagonist cetrorelix: established indications and future potential.
Engel JB, Dietl J, Rieger L, Hönig A. Expert Reviews Obstetrics and Gynecology. 2007; 2: 431-40
1. Kämmerer U, Rieger L, Honig A, Kämpgen E. Characterization of Human
Dendritic Cells at the Maternal-Fetal Interphase. Immunology of Pregnancy. Eurekah Landes Bio Science, 2004.
2. Rieger L, Kämmerer U, Singer D. Sexualfunktionen, Schwangerschaft und
Geburt. Physiologie 6. Aufl., 2009 S. 546-595. ISBN: 9783137960065
VAN DOORSLAER , PHILIPPE M. HEYNDERICKX , JO1KERMIT, Department of Applied Mathematics, Biometrics and ProcessControl, Faculty of Bioscience Engineering, Ghent University, Coupure links 653,2EnVOC, Department of Sustainable Organic Chemistry and Technology, Facultyof Bioscience Engineering, Ghent University, Coupure links 653, B-9000 Ghent,Cellular automata (CA) appeared for the first time in
FEDERAL CIRCUIT DECISIONS FOR WEEK ENDING December 13, 2013 Galderma Laboratories, L.P., v. Tolmar, Inc., (December 11, 2013) (precedential) Patent Nos. 7,579,377; 7,737,181; 7,834,060; 7,838.558; and 7,868,044. Key point(s): • Claims to a compound known to have a property at a specific concentration can be shown to be obvious by introducing prior art that teaches the usefu